NasdaqGS:CBPO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Republic of China. More Details


Snowflake Analysis

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has China Biologic Products Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CBPO has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0.2%

CBPO

-1.2%

US Biotechs

0.4%

US Market


1 Year Return

-0.8%

CBPO

32.5%

US Biotechs

17.8%

US Market

Return vs Industry: CBPO underperformed the US Biotechs industry which returned 32.5% over the past year.

Return vs Market: CBPO underperformed the US Market which returned 17.8% over the past year.


Shareholder returns

CBPOIndustryMarket
7 Day0.2%-1.2%0.4%
30 Day2.4%2.3%6.1%
90 Day6.1%-2.6%8.9%
1 Year-0.8%-0.8%34.7%32.5%20.5%17.8%
3 Year45.2%45.2%20.0%14.0%42.3%32.9%
5 Year-1.7%-1.7%11.5%3.4%84.2%63.4%

Price Volatility Vs. Market

How volatile is China Biologic Products Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is China Biologic Products Holdings undervalued compared to its fair value and its price relative to the market?

46.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CBPO ($113.18) is trading below our estimate of fair value ($212.93)

Significantly Below Fair Value: CBPO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CBPO is poor value based on its PE Ratio (29.6x) compared to the US Biotechs industry average (29.5x).

PE vs Market: CBPO is poor value based on its PE Ratio (29.6x) compared to the US market (19.1x).


Price to Earnings Growth Ratio

PEG Ratio: CBPO is poor value based on its PEG Ratio (2.8x)


Price to Book Ratio

PB vs Industry: CBPO is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is China Biologic Products Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

10.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CBPO's forecast earnings growth (10.6% per year) is above the savings rate (2.2%).

Earnings vs Market: CBPO's earnings (10.6% per year) are forecast to grow slower than the US market (22.1% per year).

High Growth Earnings: CBPO's earnings are forecast to grow, but not significantly.

Revenue vs Market: CBPO's revenue (9.6% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: CBPO's revenue (9.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CBPO's Return on Equity is forecast to be low in 3 years time (9.6%).


Next Steps

Past Performance

How has China Biologic Products Holdings performed over the past 5 years?

12.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CBPO has high quality earnings.

Growing Profit Margin: CBPO's current net profit margins (28.7%) are lower than last year (28.9%).


Past Earnings Growth Analysis

Earnings Trend: CBPO's earnings have grown by 12.2% per year over the past 5 years.

Accelerating Growth: CBPO's earnings growth over the past year (1.8%) is below its 5-year average (12.2% per year).

Earnings vs Industry: CBPO earnings growth over the past year (1.8%) exceeded the Biotechs industry -7.1%.


Return on Equity

High ROE: CBPO's Return on Equity (9.3%) is considered low.


Next Steps

Financial Health

How is China Biologic Products Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: CBPO's short term assets ($1.4B) exceed its short term liabilities ($123.9M).

Long Term Liabilities: CBPO's short term assets ($1.4B) exceed its long term liabilities ($41.4M).


Debt to Equity History and Analysis

Debt Level: CBPO is debt free.

Reducing Debt: CBPO had no debt 5 years ago.

Debt Coverage: CBPO has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CBPO has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is China Biologic Products Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CBPO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CBPO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CBPO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBPO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CBPO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

  • Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average board tenure


CEO

Joseph Chow (58 yo)

1.42yrs

Tenure

Mr. Joseph Chow serves as Senior Advisor at U.S.-China Green Investment Management Ltd. Mr. Chow serves as Chief Executive Officer at China Biologic Products Holdings, Inc. since August 05, 2019. He served ...


Board Members

NamePositionTenureCompensationOwnership
Joseph Chow
Chairman & CEO1.42yrsno data0.29%
$ 12.6m
Yungang Lu
Independent Director8.58yrsno data0.14%
$ 6.2m
Hui Li
Director6.92yrsno data0.073%
$ 3.2m
Sean S. Shao
Independent Director12.25yrsno data0.040%
$ 1.8m
Qi Ning
Independent Director2.25yrsno datano data
Yue'e Zhang
Director2.75yrsno data0.0052%
$ 226.2k

4.8yrs

Average Tenure

57.5yo

Average Age

Experienced Board: CBPO's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

China Biologic Products Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China Biologic Products Holdings, Inc.
  • Ticker: CBPO
  • Exchange: NasdaqGS
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.367b
  • Shares outstanding: 38.58m
  • Website: https://www.chinabiologic.com

Number of Employees


Location

  • China Biologic Products Holdings, Inc.
  • Jialong International Tower
  • 18th floor
  • Beijing
  • 100125
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CBPO NBMV (Bolsa Mexicana de Valores)YesNew Common StockMXMXNJul 2006
CBPONasdaqGS (Nasdaq Global Select)YesNew Common StockUSUSDJul 2006
2CHDB (Deutsche Boerse AG)YesNew Common StockDEEURJul 2006
0YWSLSE (London Stock Exchange)YesNew Common StockGBUSDJul 2006

Biography

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Repu ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 05:17
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.